Reports say the White House plans to put NIH grantmaking under political control through a committee that could review and potentially veto scientific grants. The proposal, described as tied to an executive order and reported by outlets including The New York Times and Politico, would alter the NIH’s traditional independent peer review model. Advocates and scientists criticized the move as a shift from science-led funding to ideologically driven oversight. Specific figures cited in reporting include NIH leadership and political appointees; critics argue that Congress had already blocked similar rule changes earlier in the year. The policy debate matters for biotech because NIH funding shapes upstream basic research and investigator-led translational work that feeds drug discovery pipelines, early platform development, and early clinical trial concepts. If implemented as described, the governance change could reshape timelines and priorities across the biomedical research ecosystem that biotech relies on.